Market Catalysts — 2026-10-07

Rolling 7-day window, updated daily.

464 catalyst events from 1591 relevance-filtered articles across a broad ETF and equity universe. Counts are market-wide and imply no position.

📈 Coverage acceleration — what the market just started talking about

Each symbol is compared against its own prior baseline, so a permanently-covered mega-cap has to jump a long way to appear here. This is the section to read first: ranking by raw volume just returns the same handful of mega-caps every day.

A high ratio means unusual attention, not a recommendation — it can equally reflect bad news. Use it as a starting point for research.

Catalysts by type

Most-covered stories

• CEG M_AND_A ×43 — Google Signs Nuclear Deal With Constellation Energy - The Motley Fool (google_news)
• AVGO EARNINGS ×38 — Broadcom's AI Revenue Is Growing at 221%. Here's Why Custom Chips Could Be a Bigger Business Than GPUs. (yahoo_finance)
• RKLB PRODUCT ×34 — Rocket Lab Booked 20 Launches Through 2031. The Catch Is in the Price. (yahoo_finance)
• NVDA EARNINGS ×33 — Nvidia Isn’t the Only Company Getting Rich From the AI Boom (yahoo_finance)
• LW EARNINGS ×29 — LW Q3 Deep Dive: Stable Volumes and Cost Initiatives Offset Margin Compression (yahoo_finance)
• PLTR EARNINGS ×28 — Palantir or Snowflake: If I Had to Pick 1 AI Data Stock and Never Look at It Again, This Is It (yahoo_finance)
• WBD M_AND_A ×23 — In Paramount’s cash merger, director Levy disposes of Warner Bros. Discovery (WBD) shares. - Stock Titan (google_news)
• NVDA PRODUCT ×22 — What Does Nvidia (NVDA) Gain From $40 Billion AI Demand Backing? (yahoo_finance)
• MRVL EARNINGS ×19 — Analysts upgrade TD Cowen, lift price targets after AI-focused analyst day (yahoo_finance)
• AMD EARNINGS ×19 — AMD Plans a Big 2027 Supply Ramp. Wall Street Already Expects $38 Billion of New Revenue. (yahoo_finance)
• KO EARNINGS ×19 — What You Can Take From Coca Cola HBC's 30% Gain And It Was Not Revenue - Simply Wall Street (google_news)
• MRNA DOWNGRADE ×19 — Moderna Climbs 3% Despite Citigroup’s Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water (yahoo_finance)

Research

Which catalyst types actually precede excess returns — and which of our own strategies we have tested and rejected — are on the research page. That analysis changes quarterly, so it lives apart from this daily page.

BayTradar publishes market research only. No positions, portfolio holdings, or account data are disclosed. Nothing here is financial advice.